Identification of the Mechanism of Action of a Glucokinase Activator From Oral Glucose Tolerance Test Data in Type 2 Diabetic Patients Based on an Integrated Glucose‐Insulin Model
A mechanistic drug‐disease model was developed on the basis of a previously published integrated glucose‐insulin model by Jauslin et al. A glucokinase activator was used as a test compound to evaluate the model's ability to identify a drug's mechanism of action and estimate its effects on glucose and insulin profiles following oral glucose tolerance tests. A kinetic‐pharmacodynamic approach was chosen to describe the drug's pharmacodynamic effects in a dose‐response‐time model. Four possible mechanisms of action of antidiabetic drugs were evaluated, and the corresponding affected model parameters were identified: insulin secretion, glucose production, insulin effect on glucose elimination, and insulin‐independent glucose elimination. Inclusion of drug effects in the model at these sites of action was first tested one‐by‐one and then in combination. The results demonstrate the ability of this model to identify the dual mechanism of action of a glucokinase activator and describe and predict its effects: Estimating a stimulating drug effect on insulin secretion and an inhibiting effect on glucose output resulted in a significantly better model fit than any other combination of effect sites. The model may be used for dose finding in early clinical drug development and for gaining more insight into a drug candidate's mechanism of action.
Number of times cited according to CrossRef: 13
- Karen Schneck, Lai San Tham, Ali Ertekin and Jesus Reviriego, Toward Better Understanding of Insulin Therapy by Translation of a PK‐PD Model to Visualize Insulin and Glucose Action Profiles, The Journal of Clinical Pharmacology, 59, 2, (258-270), (2018).
- Moustafa M. A. Ibrahim, Sebastian Ueckert, Svetlana Freiberga, Maria C. Kjellsson and Mats O. Karlsson, Model-Based Conditional Weighted Residuals Analysis for Structural Model Assessment, The AAPS Journal, 10.1208/s12248-019-0305-2, 21, 3, (2019).
- Pablo Morentin Gutierrez, James Yates, Catarina Nilsson and Sue Birtles, Evolving data analysis of an Oral Lipid Tolerance Test toward the standard for the Oral Glucose Tolerance Test: Cross species modeling effects of AZD7687 on plasma triacylglycerol, Pharmacology Research & Perspectives, 7, 2, (2019).
- Moustafa M. A. Ibrahim, Siti M. S. Ghadzi, Maria C. Kjellsson and Mats O. Karlsson, Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests, CPT: Pharmacometrics & Systems Pharmacology, 7, 7, (432-441), (2018).
- Gustaf J. Wellhagen, Mats O. Karlsson and Maria C. Kjellsson, Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes, CPT: Pharmacometrics & Systems Pharmacology, 7, 5, (331-341), (2018).
- SM Sheikh Ghadzi, MO Karlsson and MC Kjellsson, Implications for Drug Characterization in Glucose Tolerance Tests Without Insulin: Simulation Study of Power and Predictions Using Model‐Based Analysis, CPT: Pharmacometrics & Systems Pharmacology, 6, 10, (686-694), (2017).
- Xiaosu Ma, Jenny Y. Chien, Jennal Johnson, James Malone and Vikram Sinha, Simulation-Based Evaluation of Dose-Titration Algorithms for Rapid-Acting Insulin in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antihyperglycemic Medications, Diabetes Technology & Therapeutics, 19, 8, (483), (2017).
- Oskar Alskär, Mats O. Karlsson and Maria C. Kjellsson, Model‐Based Interspecies Scaling of Glucose Homeostasis, CPT: Pharmacometrics & Systems Pharmacology, 6, 11, (778-786), (2017).
- Joanna Parkinson, Bengt Hamrén, Maria C. Kjellsson and Stanko Skrtic, Application of the integrated glucose–insulin model for cross‐study characterization of T2DM patients on metformin background treatment, British Journal of Clinical Pharmacology, 82, 6, (1613-1624), (2016).
- Leticia P. Roma, Jessica Duprez and Jean-Christophe Jonas, Glucokinase activation is beneficial or toxic to cultured rat pancreatic islets depending on the prevailing glucose concentration, American Journal of Physiology-Endocrinology and Metabolism, 309, 7, (E632), (2015).
- Michael G. Zager, Kirk Kozminski, Bernadette Pascual, Kathleen M. Ogilvie and Shaoxian Sun, Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes, Journal of Pharmacokinetics and Pharmacodynamics, 41, 2, (127), (2014).
- Steve Choy, Emilie Hénin, Jan-Stefan van der Walt, Maria C. Kjellsson and Mats O. Karlsson, Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model, Journal of Pharmacokinetics and Pharmacodynamics, 40, 1, (1), (2013).
- Karen B. Schneck, Xin Zhang, Robert Bauer, Mats O. Karlsson and Vikram P. Sinha, Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model, Journal of Pharmacokinetics and Pharmacodynamics, 40, 1, (67), (2013).